Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela N Munster

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Expert Opinion on Investigational Drugs|March 1, 2006
Arzoxifene: the development and clinical outcome of an ideal SERMPamela N Munster
Oncology (Williston Park, N.Y.)|August 6, 2013
Fertility preservation and breast cancer: A complex problemPamela N Munster
Cancer Letters|February 3, 2009
Histone deacetylase inhibitor induced modulation of anti-estrogen therapyScott Thomas, Pamela N Munster
Expert Opinion on Pharmacotherapy|May 3, 2014
New protein kinase inhibitors in breast cancer: afatinib and neratinibXiaosong Zhang, Pamela N Munster
Cancer Control : Journal of the Moffitt Cancer Center|January 7, 2003
Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancerSusan E Minton, Pamela N Munster
Oncotargets and Therapy|December 20, 2022
Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadErica S Tsang, Pamela N Munster
Expert Opinion on Investigational Drugs|October 12, 2011
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanomaPamela N Munster, Adil I Daud
Epigenomics|December 1, 2011
Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistanceParomita Raha, Scott Thomas, Pamela N Munster
Epigenomics|June 26, 2015
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapyJeenah Park, Scott Thomas, Pamela N Munster
Immunotherapy|May 21, 2016
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitorsManuela Terranova-Barberio, Scott Thomas, Pamela N Munster
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|March 1, 2006
Arzoxifene: the development and clinical outcome of an ideal SERMPamela N Munster
Oncology (Williston Park, N.Y.)|August 6, 2013
Fertility preservation and breast cancer: A complex problemPamela N Munster
Cancer Letters|February 3, 2009
Histone deacetylase inhibitor induced modulation of anti-estrogen therapyScott Thomas, Pamela N Munster
Expert Opinion on Pharmacotherapy|May 3, 2014
New protein kinase inhibitors in breast cancer: afatinib and neratinibXiaosong Zhang, Pamela N Munster
Cancer Control : Journal of the Moffitt Cancer Center|January 7, 2003
Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancerSusan E Minton, Pamela N Munster
Oncotargets and Therapy|December 20, 2022
Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadErica S Tsang, Pamela N Munster
Expert Opinion on Investigational Drugs|October 12, 2011
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanomaPamela N Munster, Adil I Daud
Epigenomics|December 1, 2011
Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistanceParomita Raha, Scott Thomas, Pamela N Munster
Epigenomics|June 26, 2015
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapyJeenah Park, Scott Thomas, Pamela N Munster
Immunotherapy|May 21, 2016
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitorsManuela Terranova-Barberio, Scott Thomas, Pamela N Munster
Pageof 9